GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (FRA:8SJ) » Definitions » Revenue

Shanghai Junshi Biosciences Co (FRA:8SJ) Revenue : €16.09 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Shanghai Junshi Biosciences Co Revenue?

Shanghai Junshi Biosciences Co's revenue for the three months ended in Mar. 2024 was €48.65 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €16.09 Mil. Shanghai Junshi Biosciences Co's Revenue per Share for the three months ended in Mar. 2024 was €0.05. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.02.

Warning Sign:

Shanghai Junshi Biosciences Co Ltd revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Shanghai Junshi Biosciences Co was -82.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -10.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 179.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 8 years, Shanghai Junshi Biosciences Co's highest 3-Year average Revenue per Share Growth Rate was 1302.80% per year. The lowest was -10.10% per year. And the median was 468.30% per year.


Shanghai Junshi Biosciences Co Revenue Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Revenue Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 99.46 200.48 559.24 196.81 192.97

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.58 53.43 -85.99 - 48.65

Competitive Comparison of Shanghai Junshi Biosciences Co's Revenue

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Revenue falls into.



Shanghai Junshi Biosciences Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (FRA:8SJ) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Shanghai Junshi Biosciences Co Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (FRA:8SJ) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (FRA:8SJ) Headlines

No Headlines